文献速递骨软组织肉瘤与黑色素瘤胸部肿瘤头颈与中枢神经肿瘤

靶向IL1RAP的抗体偶联药物可强效作用于多种融合基因驱动肿瘤的原发与转移病灶

IL1RAP Antibody-Drug Conjugates Potently Target Primary and Metastatic Diseases in Multiple Oncofusion-Driven Cancers.
PubMed 文献 · Cancer Discov · 2026-01-01

本文基于前期发现EWSR1-ETS融合可直接诱导尤文肉瘤细胞表面表达IL1RAP,而IL1RAP在除胎盘外的健康组织中表达有限,遂构建携带不同细胞毒性载荷的抗IL1RAP抗体偶联药物(ADC)。研究显示该ADC在小鼠中强效抑制肿瘤生长、诱导尤文肉瘤移植瘤持久消退并减少体内转移播散;NPM-ALK(间变性大细胞淋巴瘤)与ETV6-NTRK3(多种肿瘤)等其他致癌融合同样诱导IL1RAP表达,使这些恶性肿瘤对IL1RAP靶向ADC敏感。非人灵长类中未检测到正常组织毒性,支持进一步临床转化。

要点

  • IL1RAP在EWSR1-ETS、NPM-ALK、ETV6-NTRK3等致癌融合驱动的肿瘤中表面表达升高,可作为ADC靶点。
  • 抗IL1RAP ADC在小鼠中抑制肿瘤生长、诱导尤文肉瘤移植瘤持久消退并减少转移。
  • 非人灵长类中未检测到正常组织毒性,支持推进临床转化。

核心结论

  • 致癌融合诱导的IL1RAP表面表达使多种恶性肿瘤对IL1RAP靶向ADC敏感,且该ADC在原发与转移疾病中均显示强效并具良好耐受性,值得进一步临床转化。

研究设计与样本

  • 临床前研究:以不同细胞毒性载荷构建靶向IL1RAP的抗体偶联药物(ADC),在小鼠尤文肉瘤移植瘤、ALCL移植瘤及同系ETV6-NTRK3+肉瘤模型中评价疗效,并在非人灵长类中评估毒性。

主要发现

  • ADC强效阻断肿瘤生长并诱导小鼠尤文肉瘤移植瘤持久消退,同时减少体内转移播散。
  • NPM-ALK(间变性大细胞淋巴瘤)与ETV6-NTRK3(多种肿瘤类型)等其他致癌融合也诱导IL1RAP表达,使这些恶性肿瘤对IL1RAP靶向ADC敏感。
  • IL1RAP靶向ADC有效阻断ALCL移植瘤及同系ETV6-NTRK3+肉瘤的生长。
  • 在包括非人灵长类在内的模型中未检测到正常组织毒性。

临床怎么用

  • 对携带EWSR1-ETS、NPM-ALK、ETV6-NTRK3等致癌融合的肿瘤,可考虑检测IL1RAP表面表达以筛选IL1RAP靶向ADC的潜在获益人群(尚处临床前阶段)。

局限性

  • 证据均来自临床前小鼠模型与非人灵长类毒性评估,尚无人体临床数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Gene fusions generated by chromosomal rearrangements function as oncogenic drivers in human cancers. We previously showed that EWSR1-ETS oncofusions of Ewing sarcoma directly induce surface expression of IL1 receptor accessory protein (IL1RAP), which along with limited expression in healthy tissues except in the placenta nominate IL1RAP as a promising Ewing sarcoma immunotherapy target. We therefore engineered antibody-drug conjugates (ADC) with different cytotoxic payloads to target IL1RAP. ADCs potently blocked tumor growth and induced durable regression of Ewing sarcoma xenografts in mice and diminished metastatic dissemination in vivo. Moreover, we show that other oncofusions also induce IL1RAP expression in diverse cancers, including NPM-ALK in anaplastic large cell lymphoma and ETV6-NTRK3 in multiple tumor types. IL1RAP expression rendered these malignancies similarly vulnerable to IL1RAP-targeting ADCs, which effectively blocked the growth of ALCL xenografts and syngeneic ETV6-NTRK3+ sarcomas. Lack of detectable normal tissue toxicity, including in nonhuman primates, supports the further clinical translation of IL1RAP-targeting ADCs. SIGNIFICANCE: The IL1RAP surface protein is induced by multiple oncogenic fusions, including EWSR1-ETS, NPM-ALK, and EN in distinct malignancies, rendering these cancers vulnerable to anti-IL1RAP ADCs. We demonstrate that IL1RAP-targeting ADCs have potent efficacy in both primary and metastatic diseases and are well tolerated in nonhuman primates, warranting their further clinical translation.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Zhang HF, De Dreuzy E, Huang YZ, et al. IL1RAP Antibody-Drug Conjugates Potently Target Primary and Metastatic Diseases in Multiple Oncofusion-Driven Cancers. Cancer Discov. 2026. PMID: 41973074. doi:10.1158/2159-8290.CD-25-1036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。